Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

The right questions key to assessing CRO performance, says study team

By Gareth MacDonald+, 09-Nov-2011

Related topics: Clinical Development, Phase I-II, Phase III-IV

Asking the right questions is key to giving pharmaceutical industry contract managers the information they need to select the best CRO partners according to the team behind a new performance assessment project.

Loading...

Interview with Dr Michael Howley
Associate Clinical Professor , LeBow College of Business, Drexel University

In the second of a series of podcasts Outsourcing-pharma.com spoke with Michael Howley, associate Clinical Professor at Drexel University’s Lebow College of Business, who said the various methods commonly used to measure performance are not always sufficiently detailed.

The first is a fairly general approach were they ask senior pharmaceutical managers something like ‘How satisfied were you with CRO performance?’ and ‘Would you recommend them?’ which are fine questions, but are not detailed enough to give the contract manager that is thinking of hiring that CRO again any insight.”

The second common approach, Howley continued, is often too detailed.

You get question like ‘how many days did it take to recruit subjects for this trial?’ with answers like ‘their average patient recruiting time is 55 days’. Does this mean that the CRO is good at recruiting patients?”

Instead Howley, in partnership with CRO Analytics’ Peter Malamis , is developing an approach that is somewhere between the established methods by asking pharma functional managers how the CRO performed in individual tasks that are important to a successful trial.

We found that the best way to ask these questions is to break them into four stages and in that way we can reach the functional areas managers within the pharmaceutical firms that are actually overseeing [the CROs} and in a legal sense are witnesses to what the CRO actually did.”

So in the patient recruitment phase we would ask ‘how well did the CRO keep you informed of its progress; in the sales and contracting phase ‘how well did they perform in the bid defence?”; later on towards the end of study conduct ‘we ask about the CROs data management practices?’”

This, he continued, enables the gathering of information on discrete tasks which, when bundled together, lead to a more accurate and useful measure of CRO performance.

Howley also urged any Outsourcing-pharma.com readers who are interested in participating in the project during the validation stage to contact him directly at mikehowley@drexel.edu .

 R&D and commercial work together to design trials, says DIA

R&D and commercial work together to design trials, says DIA

Zoran Antonijevic

Senior director of the centre for statistics in drug development...

SGS adds formulation development services and expands US lab

SGS adds formulation development services and expands US lab

Eric Hoffman

VP Business development and marketing - North America, SGS Life...

Catalent eyes emerging market expansion of end-to-end development service model

Carolyn Finkle

VP of global regulatory consulting , Catalent

European CMO market will double in just 6 years, says Frost & Sullivan

European CMO market will double in just 6 years, says Frost & Sullivan

Aiswariya Chidambaram

Healthcare market analyst, Frost & Sullivan

Almac sees growing demand for non-GMP contracting

Almac sees growing demand for non-GMP contracting

David Downey

VP Commercial Operations, Almac Pharma Services

The right questions key to assessing CRO performance, says study team

The right questions key to assessing CRO performance, says study team

Dr Michael Howley

Associate Clinical Professor , LeBow College of Business, Drexel University

CROs' complex demands are changing the tissue supply biz, says industry expert

CROs' complex demands are changing the tissue supply biz, says industry expert

Vadim Alexandre

equity analyst, Daniel Stewart & Company

Patient Recruitment Outsourcing in emerging markets: the good, the bad, and the ugly

Shaylyn Pike

Head of emerging markets research team, Cutting Edge Information

Patient recruitment must evolve, says Cutting Edge Information

Patient recruitment must evolve, says Cutting Edge Information

Eric Bolesh

Director of research, Cutting Edge Information

Patient recruitment best outsourced, says market analyst

Patient recruitment best outsourced, says market analyst

Eric Bolesh

Director of research, Cutting Edge Information

Realistic, evidence-based patient recruitment goals are key, Shire

Joseph Kim

Director of Clinical Operations, Shire Pharmaceuticals

Firecrest's site performance software goes mobile

Firecrest's site performance software goes mobile

Nigel Hughes

Head of Business Development, Firecrest Clinical

Parexel CEO reflects on Pfizer deal

Parexel CEO reflects on Pfizer deal

Joseph von Rickenbach

Chairman, CEO, Parexel

Biopharm waste material mix a chance to cut landfill costs

Biopharm waste material mix a chance to cut landfill costs

Lucy Russell

security shredding manager , Smurfit Kappa Recycling

Patheon launches CMC consultancy in face of restructuring plans

Patheon launches CMC consultancy in face of restructuring plans

Geoff Glass

Executive VP of global sales and marketing, Patheon

Parexel discusses transdermal drug delivery techs

Parexel discusses transdermal drug delivery techs

Ravi Harapanhalli

Principal Consultant and Practice Lead for Late Stage Product Development...

Quotient says screening of prototype formulations is crucial to drug delivery

Quotient says screening of prototype formulations is crucial to drug delivery

Peter Schole

VP, pharmaceutical sciences, Quotient Clinical

Covance adding mass spec for biosimilars

Covance adding mass spec for biosimilars

Ray Kaiser

Chief Scientific Officer, Biotechnology, Covance

Patheon mulls drug delivery tech deals to accelerate development services growth

Patheon mulls drug delivery tech deals to accelerate development services growth

Mark Kontny

President, Global Pharmaceutical Development Services, Patheon

Catalent eyes acquisitions in emerging market and drug delivery expansion

Catalent eyes acquisitions in emerging market and drug delivery expansion

Scott Houlton

President, Development and Clinical Services, Catalent

Icon sets its sights on genomics development

Icon sets its sights on genomics development

Brian O’Dwyer

senior VP for global bioanalytical services, Icon

Norwich amps up its pilot scale production capabilities at NY plant

Norwich amps up its pilot scale production capabilities at NY plant

Terry Novak

President, Norwich Pharmaceuticals

Rapid recruitment in emerging regions can overload sites; FDA

Rapid recruitment in emerging regions can overload sites; FDA

Cynthia Kleppinger

Medical Officer, Division of Scientific Investigations, CDER, FDA

Sponsors and CROs both have key role in quality; FDA

Sponsors and CROs both have key role in quality; FDA

Ann Meeker O’Connell

Acting Associate Director of Risk Science, Intelligence & Prioritization, FDA

ACRO, Quintiles, PRA and Theorem talk strategic partnering at DIA 2011

ACRO, Quintiles, PRA and Theorem talk strategic partnering at DIA 2011

The Big Pharma CRO strategic partnering model, its impact on drug development and the...

OSP meets Pfizer's REMOTE virtual trial partners at DIA 2011

OSP meets Pfizer's REMOTE virtual trial partners at DIA 2011

In June global drug giant Pfizer began what it described as the world’s first...

Quintiles talks about challenges of data management in today’s trials sector

Quintiles talks about challenges of data management in today’s trials sector

Paula Brown Stafford

President, Clinical Development, Quintiles

Fiscal benefits of drugs a priority for cash-strapped countries

Fiscal benefits of drugs a priority for cash-strapped countries

Geoff Fatzinger

director of regulatory affairs and strategic product development, INC Research

Strategic relationships are changing Pharma and CRO skillset says Parexel

Strategic relationships are changing Pharma and CRO skillset says Parexel

Joshua Schultz

corporate VP of strategic account leadership, Parexel

Synteract talks rescue studies at DIA 2011

Synteract talks rescue studies at DIA 2011

Stewart Bieler

COO, Synteract

Theorem CR talks about life after spin out at DIA 2011

Theorem CR talks about life after spin out at DIA 2011

James Pusey

CEO, Theorem Clinical Research

Parexel talks global trial regulations at DIA 2011

Parexel talks global trial regulations at DIA 2011

Alberto Grignolo

Corporate Vice President, Global Strategy and Services, Parexel International

Chiltern says strategic deals are good for the CRO sector

Chiltern says strategic deals are good for the CRO sector

Aize Smink

Senior Executive VP, Global Clinical Development, Chiltern

Quintiles launches silo busting data management platform at DIA

Quintiles launches silo busting data management platform at DIA

Thomas Grundstrom

VP of global data solutions, Quintiles

Celerion talks about research sector in South America

Celerion talks about research sector in South America

US CRO Celerion gained Brazilian National Health Surveillance Agency (Agência Nacional de Vigilancia Sanitaria...

PRA reflects on data and information management at DIA

PRA reflects on data and information management at DIA

Steve Powell

Senior VP of clinical informatics and late phase services ,...

DSA talks social media in pharma at DIA 2011

DSA talks social media in pharma at DIA 2011

Elizabeth Garrard

Chief Safety Officer, DSA

Medidata to add SaaS CTMS through Clinical Force buy

Medidata to add SaaS CTMS through Clinical Force buy

Graham Bunn

Vice president of partnerships and alliances, Medidata

Almac talks expansion at Interphex 2011

Almac talks expansion at Interphex 2011

James McGibbon

direstor of business development, pharma services, Almac

EDT talks about the contract manufacturing market at Interphex

EDT talks about the contract manufacturing market at Interphex

Philip Pratten

Vice president, manufacturing services operations, Elan Drug Technologies

Patheon talks about backup manufacturing service at Interphex 2011

Patheon talks about backup manufacturing service at Interphex 2011

Geoffrey Glass

Executive VP of Global Strategy, sales and marketing, Patheon

Follow us on